Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6710MR)

This product GTTS-WQ6710MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6710MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5656MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ11430MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ8461MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ13382MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ500MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ12220MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ10920MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ4403MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW